Ophthalix Inc (OPLI) 0.4500 $OPLI Can-Fite's CF
Post# of 273330
Posted On: 09/24/2016 5:05:51 PM
Ophthalix Inc (OPLI) 0.4500 $OPLI
Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
PR Newswire - Thu Dec 17, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that the Japan Patent Office has granted the Company a patent for its lead drug candidate CF101 for the reduction of intraocular pressure (IOP) in a patent titled, "A3 adenosine receptor agonists for the reduction of intraocular pressure." CF101 is an A3 adenosine receptor (A3AR) agonist that binds to A3AR, which is known to be over-expressed in inflammatory cells. Can-Fite has been granted a similar patent in the U.S. for IOP and has pending applications in other key global markets.
CANF: 2.63 (-0.05)
OphthaliX Announces CF101 is Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
PR Newswire - Thu Dec 17, 5:50AM CST
OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that the Japan Patent Office has granted a patent for CF101 for the reduction of intraocular pressure (IOP) in a patent titled, "A3 adenosine receptor agonists for the reduction of intraocular pressure." CF101 is an A3 adenosine receptor (A3AR) agonist that binds to A3AR, which is known to be over-expressed in inflammatory cells. Can-Fite, which licenses the ophthalmic indications of CF101 to OphthaliX, has been granted a similar patent in the U.S. for IOP and has pending applications in other key global markets.
CANF: 2.63 (-0.05)
OphthaliX Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
PR Newswire - Mon Dec 07, 6:00AM CST
OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.
CANF: 2.63 (-0.05)
Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
PR Newswire - Mon Dec 07, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that its subsidiary, OphthaliX (OTCQB:OPLI), has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.
CANF: 2.63 (-0.05)
OphthaliX Launches Updated Website to Reflect Proposed Acquisition of I.V.S.
PR Newswire - Tue Jul 14, 6:00AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
PR Newswire - Fri Jun 19, 6:00AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.) in a stock-for-stock transaction.
CANF: 2.63 (-0.05)
Can-Fite Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
PR Newswire - Fri Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced that its subsidiary, OphthaliX (OTCQB: OPLI) has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
PR Newswire - Mon May 04, 7:50AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc. (OTCQB: OPLI), has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
OphthaliX Signs Term Sheet to Acquire Improved Vision Systems Ltd.
PR Newswire - Mon May 04, 7:45AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
PR Newswire - Tue Jan 06, 6:15AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced its anticipated clinical milestones for calendar 2015.
CANF: 2.63 (-0.05)
Second Part of the Glaucoma Phase II study has been Approved in a European Country
PR Newswire - Mon Dec 15, 6:02AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly.
CANF: 2.63 (-0.05)
Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
PR Newswire - Thu Dec 17, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that the Japan Patent Office has granted the Company a patent for its lead drug candidate CF101 for the reduction of intraocular pressure (IOP) in a patent titled, "A3 adenosine receptor agonists for the reduction of intraocular pressure." CF101 is an A3 adenosine receptor (A3AR) agonist that binds to A3AR, which is known to be over-expressed in inflammatory cells. Can-Fite has been granted a similar patent in the U.S. for IOP and has pending applications in other key global markets.
CANF: 2.63 (-0.05)
OphthaliX Announces CF101 is Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
PR Newswire - Thu Dec 17, 5:50AM CST
OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that the Japan Patent Office has granted a patent for CF101 for the reduction of intraocular pressure (IOP) in a patent titled, "A3 adenosine receptor agonists for the reduction of intraocular pressure." CF101 is an A3 adenosine receptor (A3AR) agonist that binds to A3AR, which is known to be over-expressed in inflammatory cells. Can-Fite, which licenses the ophthalmic indications of CF101 to OphthaliX, has been granted a similar patent in the U.S. for IOP and has pending applications in other key global markets.
CANF: 2.63 (-0.05)
OphthaliX Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
PR Newswire - Mon Dec 07, 6:00AM CST
OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.
CANF: 2.63 (-0.05)
Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
PR Newswire - Mon Dec 07, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that its subsidiary, OphthaliX (OTCQB:OPLI), has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.
CANF: 2.63 (-0.05)
OphthaliX Launches Updated Website to Reflect Proposed Acquisition of I.V.S.
PR Newswire - Tue Jul 14, 6:00AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
PR Newswire - Fri Jun 19, 6:00AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.) in a stock-for-stock transaction.
CANF: 2.63 (-0.05)
Can-Fite Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
PR Newswire - Fri Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced that its subsidiary, OphthaliX (OTCQB: OPLI) has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
PR Newswire - Mon May 04, 7:50AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc. (OTCQB: OPLI), has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
OphthaliX Signs Term Sheet to Acquire Improved Vision Systems Ltd.
PR Newswire - Mon May 04, 7:45AM CDT
OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).
CANF: 2.63 (-0.05)
Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
PR Newswire - Tue Jan 06, 6:15AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced its anticipated clinical milestones for calendar 2015.
CANF: 2.63 (-0.05)
Second Part of the Glaucoma Phase II study has been Approved in a European Country
PR Newswire - Mon Dec 15, 6:02AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly.
CANF: 2.63 (-0.05)
(0)
(0)